Table 1 Clinical pathological data of AGC patients with synchronous liver metastasis
Clinical pathological data | Group underwent adjuvant gastrectomy | Group treated with chemotherapy only | P value |
|---|---|---|---|
Age | 61.4 ± 9.5 | 60.8 ± 7.9 | 0.834 |
BSA | 1.758 ± 0.186 | 1.743 ± 0.142 | 0.755 |
Gender (male vs. female) | 3.2:1 | 5:1 | 0.725 |
Primary tumor location | Â | Â | 0.003 |
EGJ | 4 (16.7 %) | 0 (0 %) | Â |
U | 2 (8.3 %) | 9 (42.9 %) | Â |
M | 3 (12.5 %) | 5 (23.8 %) | Â |
L | 15 (62.5 %) | 7 (33.3 %) | Â |
Borrmann type | Â | Â | 0.355 |
I | 0 (0 %) | 0 (0 %) | Â |
II | 3 (13.6 %) | 4 (21.1 %) | Â |
III | 19 (86.4 %) | 14 (73.7 %) | Â |
IV | 0 (0 %) | 1 (5.3 %) | Â |
Histological grade | Â | Â | 0.594 |
Low differentiation | 9 (40.9 %) | 9 (45.0 %) | Â |
Median and low differentiation | 0 (0 %) | 1 (5.0 %) | Â |
Median differentiation | 4 (18.2 %) | 4 (20.0 %) | Â |
High and median differentiation | 9 (40.9 %) | 6 (30.0 %) | Â |
Pathological classification | Â | Â | 0.273 |
Adenocarcinoma | 22 (91.7 %) | 21 (100 %) | Â |
Small cell carcinoma | 1 (4.2 %) | 0 (0 %) | Â |
Signet ring cell carcinoma | 1 (4.2 %) | 0 (0 %) | Â |
T stage (TNM version 7) | Â | Â | 0.387 |
T2 | 3 (13.0 %) | 1 (5.0 %) | Â |
T3 | 1 (4.3 %) | 0 (0 %) | Â |
T4a | 17 (73.9 %) | 15 (75.0 %) | Â |
T4b | 2 (8.7 %) | 4 (20.0 %) | Â |